DAVID T. TEACHEY (PHILADELPHIA)
STANDARD AND NEW OPTIONS FOR T-ALL
David T. Teachey, MD, Associate Professor of Pediatrics, Divisions of Hematology and Oncology,
Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine
The prognosis for children and adults with T cell acute lymphoblastic leukemia (T-ALL) has improved
over recent years due to intensification of cytotoxic chemotherapy. We have reached a point where
further intensification is unlikely to increase rates of cure, and new approaches are needed to
overcome resistance to cytotoxic chemotherapy. Historically, novel therapies would translate into
the clinic in trials that included patients with B- and T-ALL. Unfortunately, recent advances in
lineage-specific immunotherapy have left T-ALL behind. The biology of T-ALL is distinct from B-ALL,
and development of targeted therapies has also historically been more B-ALL-centric. This talk will
discuss the results of recent trials in de novo and relapsed T-ALL, new insights in T-ALL biology, and
novel therapies in preclinical development and early phase trials. Gaps in knowledge and the need
for international cooperative group trials that span the age spectrum will also be discussed.
SCIENTIFIC
PROGRAMME
RARE SUBSETS OF
ACUTE LEUKAEMIA
TRACKING LEUKAEMIC
STEM CELLS (LSCs)
ROUTINE DIAGNOSIS
GENE EXPRESSION
AND MUTATIONAL
PROFILING
DEBATE 1 – ALL
PATIENTS WITH
INTERMEDIATE-RISK
AML MUST BE
TRANSPLANTED
INTERACTIVE
CASES 1 – MUTATION-BASED
THERAPY
OFF-LABEL
ROUNDTABLE –
SHOULD WE REALLY
USE NEW TARGETED
INHIBITORS AS SINGLE
AGENTS ?
ADDITION OF A 3RD
AGENT TO FRONTLINE
7+3
ROUNDTABLE –
CURATIVE OPTIONS
FOR OLDER AML
INTERACTIVE CASES 2
DEBATE 2 - BEST
TREATMENT FOR
NPM1-MUTATED AML IN
THE NEXT FUTURE ?
ALLOGENEIC
HAEMATOPOIETIC
STEM CELL
TRANSPLANTATION
(HSCT)
IMMUNOTHERAPY FOR
ACUTE LEUKAEMIA
DEBATE 3 - T-ALL:
WHERE ARE WE GOING
NOW?
SELECTED ABSTRACTS
AND CLINICAL
CASES FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES